Statins in the primary prevention of cardiovascular disease. Rosuvastatin capabilities

The article discusses the modern principles of lipid-lowering therapy and approaches to its administration in terms of levels of cardiovascular risk. The characteristics of groups of patients with different levels of cardiovascular risk (from low to high) in primary prevention are given. The article...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marina G. Bubnova, Marianna Y. Ilchenko, Petr A. Lebedev
Formato:	article
Lenguaje:	EN RU
Publicado:	Concilium Medicum 2021
Materias:	lipid-lowering therapy statins rosuvastatin primary prevention Diseases of the circulatory (Cardiovascular) system RC666-701 Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/5f5a0142ea2a45fc9cae20eea8f53e85
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5f5a0142ea2a45fc9cae20eea8f53e85
record_format	dspace
spelling	oai:doaj.org-article:5f5a0142ea2a45fc9cae20eea8f53e852021-12-01T22:07:01ZStatins in the primary prevention of cardiovascular disease. Rosuvastatin capabilities2221-71852658-570710.26442//22217185.2021.2.200859https://doaj.org/article/5f5a0142ea2a45fc9cae20eea8f53e852021-06-01T00:00:00Zhttps://cardiosomatics.orscience.ru/2221-7185/article/viewFile/71732/52426https://doaj.org/toc/2221-7185https://doaj.org/toc/2658-5707The article discusses the modern principles of lipid-lowering therapy and approaches to its administration in terms of levels of cardiovascular risk. The characteristics of groups of patients with different levels of cardiovascular risk (from low to high) in primary prevention are given. The article defines the target levels of low- density lipoprotein cholesterol, which should be achieved with the modern lipid-lowering therapy. The clinical effects of statins in primary prevention are presented. The clinical results of two large studies of rosuvastatin that have changed the approach to statin prescribing in primary prevention are discussed. The article presents the results of the analysis of long-term follow-up of patients in the primary prevention after the completion of randomized clinical studies. Approaches to the use of statins for novel coronavirus infection are considered.Marina G. BubnovaMarianna Y. IlchenkoPetr A. LebedevConcilium Medicumarticlelipid-lowering therapystatinsrosuvastatinprimary preventionDiseases of the circulatory (Cardiovascular) systemRC666-701Diseases of the endocrine glands. Clinical endocrinologyRC648-665ENRUКардиоСоматика, Vol 12, Iss 2, Pp 110-118 (2021)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	lipid-lowering therapy statins rosuvastatin primary prevention Diseases of the circulatory (Cardiovascular) system RC666-701 Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	lipid-lowering therapy statins rosuvastatin primary prevention Diseases of the circulatory (Cardiovascular) system RC666-701 Diseases of the endocrine glands. Clinical endocrinology RC648-665 Marina G. Bubnova Marianna Y. Ilchenko Petr A. Lebedev Statins in the primary prevention of cardiovascular disease. Rosuvastatin capabilities
description	The article discusses the modern principles of lipid-lowering therapy and approaches to its administration in terms of levels of cardiovascular risk. The characteristics of groups of patients with different levels of cardiovascular risk (from low to high) in primary prevention are given. The article defines the target levels of low- density lipoprotein cholesterol, which should be achieved with the modern lipid-lowering therapy. The clinical effects of statins in primary prevention are presented. The clinical results of two large studies of rosuvastatin that have changed the approach to statin prescribing in primary prevention are discussed. The article presents the results of the analysis of long-term follow-up of patients in the primary prevention after the completion of randomized clinical studies. Approaches to the use of statins for novel coronavirus infection are considered.
format	article
author	Marina G. Bubnova Marianna Y. Ilchenko Petr A. Lebedev
author_facet	Marina G. Bubnova Marianna Y. Ilchenko Petr A. Lebedev
author_sort	Marina G. Bubnova
title	Statins in the primary prevention of cardiovascular disease. Rosuvastatin capabilities
title_short	Statins in the primary prevention of cardiovascular disease. Rosuvastatin capabilities
title_full	Statins in the primary prevention of cardiovascular disease. Rosuvastatin capabilities
title_fullStr	Statins in the primary prevention of cardiovascular disease. Rosuvastatin capabilities
title_full_unstemmed	Statins in the primary prevention of cardiovascular disease. Rosuvastatin capabilities
title_sort	statins in the primary prevention of cardiovascular disease. rosuvastatin capabilities
publisher	Concilium Medicum
publishDate	2021
url	https://doaj.org/article/5f5a0142ea2a45fc9cae20eea8f53e85
work_keys_str_mv	AT marinagbubnova statinsintheprimarypreventionofcardiovasculardiseaserosuvastatincapabilities AT mariannayilchenko statinsintheprimarypreventionofcardiovasculardiseaserosuvastatincapabilities AT petralebedev statinsintheprimarypreventionofcardiovasculardiseaserosuvastatincapabilities
_version_	1718404163626336256

Statins in the primary prevention of cardiovascular disease. Rosuvastatin capabilities

Ejemplares similares